EEG as a translational biomarker and outcome measure in fragile X syndrome
Abstract Targeted treatments for fragile X syndrome (FXS) have frequently failed to show efficacy in clinical testing, despite success at the preclinical stages. This has highlighted the need for more effective translational outcome measures. EEG differences observed in FXS, including exaggerated N1...
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Nature Publishing Group
2022-01-01
|
| Series: | Translational Psychiatry |
| Online Access: | https://doi.org/10.1038/s41398-022-01796-2 |